U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06822946) titled 'Zhibitai Capsules for the Treatment of Primary Hyperlipidemia' on Feb. 07.
Brief Summary: Exploring the benefit risk ratio of increase in dosage of Zhibitai capsules (2 capsules at a time, 2 times a day) compared to the original dosage (1 capsule at a time, 1 day)
Study Start Date: Feb. 14
Study Type: INTERVENTIONAL
Condition:
Primary Hyperlipidemia
Intervention:
DRUG: zhibitai capsule
2 capsule of Zhibitai capsule/time, 2 times/day, oral
DRUG: zhibitai capsule
(1 capsule of Zhibitai capsules+1 capsule of Zhibitai capsule simulant)/time, 2 times/day, oral
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chengdu Diao Jiuhon...